Jörg Wischhusen

9.1k total citations · 2 hit papers
91 papers, 6.7k citations indexed

About

Jörg Wischhusen is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Jörg Wischhusen has authored 91 papers receiving a total of 6.7k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Immunology, 33 papers in Oncology and 30 papers in Molecular Biology. Recurrent topics in Jörg Wischhusen's work include Immune Cell Function and Interaction (13 papers), Immunotherapy and Immune Responses (11 papers) and GDF15 and Related Biomarkers (9 papers). Jörg Wischhusen is often cited by papers focused on Immune Cell Function and Interaction (13 papers), Immunotherapy and Immune Responses (11 papers) and GDF15 and Related Biomarkers (9 papers). Jörg Wischhusen collaborates with scholars based in Germany, United States and Switzerland. Jörg Wischhusen's co-authors include Michael Weller, Christoph P. Beier, Dagmar Beier, J. Dietl, Peter Hau, Alexander Brawanski, Martin Proescholdt, Wolfgang Wick, Wolf H. Fridman and Sebastian Häusler and has published in prestigious journals such as Journal of Neuroscience, Nature reviews. Cancer and The Journal of Immunology.

In The Last Decade

Jörg Wischhusen

88 papers receiving 6.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CD133+ and CD133− Glioblastoma-Derived Cancer Stem Cells Show Differential Growth Characteristics and Molecular Profiles

2007 876 citations Dagmar Beier, Peter Hau et al. Cancer Research profile →
Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint

2020 333 citations Jörg Wischhusen et al. profile →

Peers

Countries citing papers authored by Jörg Wischhusen

Since Specialization

Citations

This map shows the geographic impact of Jörg Wischhusen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jörg Wischhusen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jörg Wischhusen more than expected).

Fields of papers citing papers by Jörg Wischhusen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jörg Wischhusen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jörg Wischhusen. The network helps show where Jörg Wischhusen may publish in the future.

Co-authorship network of co-authors of Jörg Wischhusen

This figure shows the co-authorship network connecting the top 25 collaborators of Jörg Wischhusen. A scholar is included among the top collaborators of Jörg Wischhusen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jörg Wischhusen. Jörg Wischhusen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Remote Exercise Training Intervention During the COVID-19 Pandemic: Randomized Controlled Trial 2024 ·Journal of Medical Internet Research ·(unknown), (unknown), Alexandra Brahmer, Elmo W. I. Neuberger, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Jörg Wischhusen, Beat Lutz, Klaus Lieb, Michèle Wessa, Perikles Simon	1
2	12P Immuno-suppressive role of tumour-derived GDF-15 on myeloid cells 2023 ·Annals of Oncology ·Christine Schuberth-Wagner, (unknown), Manfred Kist, (unknown), Sabrina Genßler, (unknown), (unknown), Michael Auer, Jörg Wischhusen, (unknown), Eugen Leo, Markus Haake	1
3	Versatile guardians: regenerative regulatory T cells in Parkinson’s disease rodent models 2023 ·Signal Transduction and Targeted Therapy ·Chi Wang Ip, Jörg Wischhusen	4
4	Performance of Three SARS-CoV-2 Immunoassays, Three Rapid Lateral Flow Tests, and a Novel Bead-Based Affinity Surrogate Test for the Detection of SARS-CoV-2 Antibodies in Human Serum 2021 ·Journal of Clinical Microbiology ·Manuel Krone, (unknown), Johannes Wagener, Thiên‐Trí Lâm, Christoph Schoen, Ulrich Vogel, August Stich, (unknown), Jörg Wischhusen, Thomas Kerkau, Niklas Beyersdorf, (unknown), Simone Backes, Lars Dölken, Georg Gasteiger, Oliver Kurzai, Alexandra Schubert‐Unkmeir	14
5	Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1) 2014 ·Cell Death and Disease ·(unknown), Valentin Bruttel, Roland Stein, Evi Horn, Sebastian Häusler, J. Dietl, A Hönig, Jörg Wischhusen	56
6	Urinary TIMP-1 and MMP-2 levels detect the presence of pancreatic malignancies 2014 ·British Journal of Cancer ·R ROY, David Zurakowski, Jörg Wischhusen, Christine Frauenhoffer, Susanne M. Hooshmand, Matthew H. Kulke, Marsha A. Moses	60
7	Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity 2011 ·Cancer Immunology Immunotherapy ·Sebastian Häusler, I Montalban del Barrio, (unknown), P. Anoop Chandran, J. Engel, A Hönig, (unknown), Evi Horn, (unknown), Mathias Krockenberger, Stefan Heuer, Ahmed Adel Seida, Markus Junker, Hermann Kneitz, Doris Kloor, Karl‐Norbert Klotz, J. Dietl, Jörg Wischhusen	153
8	Transcriptional Profiles of CD133+ and CD133− Glioblastoma-Derived Cancer Stem Cell Lines Suggest Different Cells of Origin 2010 ·Cancer Research ·Claudio Lottaz, Dagmar Beier, Katharina Meyer, Praveen Kumar, Andreas Hermann, Johannes Schwarz, Markus Junker, Peter J. Oefner, Ulrich Bogdahn, Jörg Wischhusen, Rainer Spang, Alexander Storch, Christoph P. Beier	207
9	Immunoselection of Breast and Ovarian Cancer Cells with Trastuzumab and Natural Killer Cells: Selective Escape of CD44high/CD24low/HER2low Breast Cancer Stem Cells 2009 ·Cancer Research ·(unknown), Yvonne Dombrowski, Cathrin Ritter, Mathias Buttmann, Sebastian Häusler, (unknown), Mathias Krockenberger, Dagmar Beier, Christoph P. Beier, J. Dietl, Jürgen C. Becker, A Hönig, Jörg Wischhusen	101
10	Temozolomide Preferentially Depletes Cancer Stem Cells in Glioblastoma 2008 ·Cancer Research ·Dagmar Beier, (unknown), Deepu R. Pillai, Stefanie Schwarz, Leoni A. Kunz‐Schughart, Petra Leukel, Martin Proescholdt, Alexander Brawanski, Ulrich Bogdahn, (unknown), Bernd Giebel, Jörg Wischhusen, Guido Reifenberger, Peter Hau, Christoph P. Beier	232
11	Macrophage Migration Inhibitory Factor Contributes to the Immune Escape of Ovarian Cancer by Down-Regulating NKG2D 2008 ·The Journal of Immunology ·Mathias Krockenberger, Yvonne Dombrowski, Claudia Weidler, (unknown), A Hönig, Sebastian Häusler, Heike Voigt, Jürgen C. Becker, Lin Leng, Alexander Steinle, Michael Weller, Richard Bucala, J. Dietl, Jörg Wischhusen	136
12	Melanoma stem cells: targets for successful therapy? 2008 ·JDDG Journal der Deutschen Dermatologischen Gesellschaft ·Roland Houben, Jörg Wischhusen, Farid Menaa, (unknown), David Schrama, Eva‐Bettina Bröcker, Jürgen C. Becker	8
13	CD133+ and CD133− Glioblastoma-Derived Cancer Stem Cells Show Differential Growth Characteristics and Molecular Profiles breakdown → 2007 ·Cancer Research ·Dagmar Beier, Peter Hau, Martin Proescholdt, (unknown), Jörg Wischhusen, Peter J. Oefner, Ludwig Aigner, Alexander Brawanski, Ulrich Bogdahn, Christoph P. Beier	876
14	Immune-refractory cancers and their little helpers—An extended role for immunetolerogenic MHC molecules HLA-G and HLA-E? 2007 ·Seminars in Cancer Biology ·Jörg Wischhusen, Anne Waschbisch, Heinz Wiendl	46
15	FasL (CD95L/APO-1L) Resistance of Neurons Mediated by Phosphatidylinositol 3-Kinase-Akt/Protein Kinase B-Dependent Expression of Lifeguard/Neuronal Membrane Protein 35 2005 ·Journal of Neuroscience ·Christoph P. Beier, Jörg Wischhusen, Marc Gleichmann, Ellen Gerhardt, Ana Pekanovic, Andreas Krueger, Verdon Taylor, Ueli Suter, Peter H. Krammer, Matthias Endres, Michael Weller, Jörg B. Schulz	49
16	Death receptor-mediated apoptosis in human malignant glioma cells: Modulation by the CD40/CD40L system 2005 ·Journal of Neuroimmunology ·Jörg Wischhusen, Dagmar Schneider, Michel Mittelbronn, Richard Meyermann, Hartmut Engelmann, Gundram Jung, Heinz Wiendl, Michael Weller	28
17	Immune stimulatory effects of CD70 override CD70‐mediated immune cell apoptosis in rodent glioma models and confer long‐lasting antiglioma immunity in vivo 2005 ·International Journal of Cancer ·Steffen Aulwurm, Jörg Wischhusen, Manuel A. Friese, Jannie Borst, Michael Weller	31
18	CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death 2003 ·Oncogene ·Jörg Wischhusen, Ulrike Naumann, Hideaki Ohgaki, Farzan Rastinejad, Michael Weller	134
19	A Functional Role of HLA-G Expression in Human Gliomas: An Alternative Strategy of Immune Escape 2002 ·The Journal of Immunology ·Heinz Wiendl, Meike Mitsdoerffer, Valeska Hofmeister, Jörg Wischhusen, Antje Bornemann, Richard Meyermann, Elisabeth H. Weiss, Arthur Melms, Michael Weller	291
20	N‐[3,4‐dimethoxycinnamoyl]‐anthranilic acid (tranilast) suppresses microglial inducible nitric oxide synthase (iNOS) expression and activity induced by interferon‐γ (IFN‐γ) 2001 ·British Journal of Pharmacology ·Michael Platten, Wolfgang Wick, Jörg Wischhusen, Michael Weller	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact